We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PARP inhibition utilized in combination therapy with Olaparib‐Temozolomide to achieve disease stabilization in a rare case of BRCA1‐mutant, metastatic myxopapillary ependymoma.
- Authors
Mahalingam, Preethika; Smith, Sam; Lopez, Juanita; Sharma, Rajaei K; Millard, Thomas; Thway, Khin; Fisher, Cyril; Reardon, David A; Jones, Robin; Nicholson, Andrew G; Cunningham, David; Welsh, Liam; Sharma, Bhupinder
- Abstract
Myxopapillary ependymoma (MPE) is a primary tumor of the central nervous system (CNS), characteristically an indolent malignancy involving the spinal conus medullaris, Filum terminale or cauda equina. We present a rare case of MPE, recurrent in the pelvic soft tissue with eventual pleural and intra-pulmonary metastasis. Refractory to repeated gross resection, adjuvant radiotherapy, platinum-based chemotherapy and temozolomide exploitation of mutant somatic BRCA1 status with the addition of a poly (ADP-ribose); polymerase inhibitor (PARPi) in a novel combination regimen with olaparib-temozolomide (OT) has achieved stable radiological disease after 10 cycles.
- Subjects
EPENDYMOMA; CENTRAL nervous system tumors; POLY(ADP-ribose) polymerase; CAUDA equina; REOPERATION
- Publication
Rare Tumors, 2023, p1
- ISSN
2036-3605
- Publication type
Case Study
- DOI
10.1177/20363613231152333